GLP-1 Weight Loss Calculator
Estimate your potential weight loss on semaglutide or tirzepatide based on clinical trial averages.
Disclaimer: This calculator provides estimates based on clinical trial averages. Individual results vary significantly. This is not medical advice.
Estimate Your Weight Loss
How This Calculator Works
This calculator applies average weight loss percentages from major clinical trials:
- Semaglutide: Based on STEP trial data showing ~15% average weight loss at 68 weeks at 2.4mg dose
- Tirzepatide: Based on SURMOUNT trial data showing ~21% average weight loss at 72 weeks at 15mg dose
Your actual results may be higher or lower depending on your starting BMI, adherence to diet and exercise, dose titration schedule, and individual biology.
Frequently Asked Questions
How accurate is this calculator?
This calculator uses average weight loss percentages from clinical trials (STEP and SURMOUNT). Individual results vary significantly based on dose, diet, exercise, genetics, and starting BMI. Use these numbers as rough estimates, not guarantees.
Does starting weight affect how much you lose?
Yes. Patients with higher starting weights typically lose more total pounds but a similar percentage of body weight. A 300-pound person losing 15% loses 45 lbs; a 200-pound person losing 15% loses 30 lbs.
Which medication produces more weight loss?
Tirzepatide produces approximately 21% average weight loss at maximum dose vs 15% for semaglutide in clinical trials. However, individual responses vary and some patients respond better to semaglutide.
When does weight loss plateau on GLP-1?
Most patients reach maximum weight loss at 12-18 months on treatment. After that, weight typically stabilizes. Plateaus during the journey are normal and usually temporary.
Ready to Start Your Journey?
Trimi offers affordable GLP-1 treatment. See what is possible for you.
Get Started TodayMore on Calculators & Tools
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).